Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA's New Paragraph IV Data Further Illustrates Generic Competition Problems

Executive Summary

Data on the number of ANDAs submitted with valid paragraph IV certifications shows some products with strong generic interest and others with almost none.


Related Content

House Vs. Senate Drug Pricing Bills: A Snapshot Of Differences
Complex Generic Mid-Cycle Meetings: US FDA Suggests Taking The Date Offered
Generic Industry Market Forces May Impact GDUFA III Talks
Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts